Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)

29 września 2015 zaktualizowane przez: Otsuka Pharmaceutical Development & Commercialization, Inc.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

636

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Japonia
      • Kumamoto-shi, Japonia, 861-8002
    • Kanagawa-Ken
      • Fujisawa-shi, Kanagawa-Ken, Japonia, 251-8530
    • Okinawa-Ken
      • Kunigami-gun, Okinawa-Ken, Japonia, 904-1201
    • Osaka-Fu
      • Sakai-shi, Osaka-Fu, Japonia, 590-0018
    • Tokyo-To
      • Setagaya-ku, Tokyo-To, Japonia, 156-0057
  • Kanada
    • Ontario
      • Burlington, Ontario, Kanada, L7R 4E2
      • Chatham, Ontario, Kanada, N7M 5L9
      • Chatham, Ontario, Kanada, N7L 1B7
  • Polska
      • Choroszcz, Polska, 16-070
      • Gdansk, Polska, 80-952
      • Gdansk, Polska, 80-282
      • Lodz, Polska, 91-229
  • Republika Korei
      • Incheon, Republika Korei, 405-760
      • Incheon, Republika Korei, 400-711
      • Seoul, Republika Korei, 136-705
      • Seoul, Republika Korei, 137-710
      • Seoul, Republika Korei, 143-711
  • Rumunia
      • Arad, Rumunia, 310022
      • Bucuresti, Rumunia, 010825
      • Bucuresti, Rumunia, 041914
      • Bucuresti, Rumunia, 030442
      • Cluj-Napoca, Rumunia, 400012
      • Focsani, Rumunia, 620165
      • Pitesti, Rumunia, 110069
      • Targoviste, Rumunia, 130086
  • Serbia
      • Belgrade, Serbia, 11000
      • Kragujevac, Serbia, 34000
      • Novi Sad, Serbia, 21000
  • Stany Zjednoczone
    • Arkansas
      • Little Rock, Arkansas, Stany Zjednoczone, 72205
    • California
      • Garden Grove, California, Stany Zjednoczone, 92845
      • Glendale, California, Stany Zjednoczone, 91206
      • Oakland, California, Stany Zjednoczone, 94612
      • Oceanside, California, Stany Zjednoczone, 92056
      • San Diego, California, Stany Zjednoczone, 92123
      • San Diego, California, Stany Zjednoczone, 92102
    • Florida
      • Bradenton, Florida, Stany Zjednoczone, 34208
      • Miami Springs, Florida, Stany Zjednoczone, 33166
      • Orlando, Florida, Stany Zjednoczone, 32806
    • New York
      • Fresh Meadows, New York, Stany Zjednoczone, 11423
      • Jamaica, New York, Stany Zjednoczone, 11432
    • Ohio
      • Dayton, Ohio, Stany Zjednoczone, 45417
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29407
      • Charleston, South Carolina, Stany Zjednoczone, 29405
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78754
    • Washington
      • Kirkland, Washington, Stany Zjednoczone, 98033
  • Ukraina
      • Chernihiv, Ukraina, 14000
      • Dnipropetrovsk, Ukraina, 49005
      • Dnipropetrovsk, Ukraina, 49115
      • Glevakha, Ukraina, 08631
      • Kherson, Vil. Stepanivka, Ukraina, 73488
      • Kyiv, Ukraina, 02660
      • Kyiv, Ukraina, 04080
      • Lviv, Ukraina, 79021
      • Simferopol, Ukraina, 95006
      • Vinnytsia, Ukraina, 21005
  • Łotwa
      • Daugavpils, Łotwa, LV-5417
      • Jelgava, Łotwa, LV-3008
      • Liepaja, Łotwa, LV-3401
      • Riga, Łotwa, LV-1005
      • Strenci, Łotwa, LV-4730

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria
  2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia
  3. Subjects experiencing an acute exacerbation of psychotic symptoms
  4. Other protocol specific inclusion criteria may apply

Exclusion Criteria:

  1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug

  2. Subjects with a current DSM-IV-TR Axis I diagnosis of:

    • Schizoaffective disorder
    • Major depressive disorder (MDD)
    • Bipolar disorder
    • Delirium, dementia, amnestic or other cognitive disorder
    • Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
  3. Subjects presenting with a first episode of schizophrenia
  4. Other protocol specific exclusion criteria may apply

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo
Placebo, raz dziennie, przez sześć tygodni
Lek: Placebo
Placebo, raz dziennie, przez sześć tygodni
Eksperymentalny: OPC-34712 [Brexpiprazole] High Dose
Higher Dose, tablet, once daily, for six weeks
Lek: OPC-34712 [Brexpiprazole] High Dose
Higher dose, tablet, once daily, for six weeks
Eksperymentalny: OPC-34712 [Brexpiprazole] Middle Dose
Middle Dose, tablet, once daily, for six weeks
Lek: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
Middle dose, tablet, once daily, for six weeks
Eksperymentalny: OPC-34712 [Brexpiprazole] Low Dose
Lower Dose, tablet, once daily, for six weeks
Lek: Experimental: OPC-34712 [Brexpiprazole] Low Dose
Lower dose, tablet, once daily, for six weeks

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Mean Change From Baseline to Week 6 Positive and Negative Syndrome Scale (PANSS) Total Score.
Ramy czasowe: Baseline to Week 6
The PANSS consists of 3 subscales (positive subscale, negative subscale and general psychology subscale) containing a total of 30 symptom constructs and was administered using the Structured Clinical Interview (SCI)-PANSS. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Baseline to Week 6

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Mean Change From Baseline to Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
Ramy czasowe: Baseline to Week 6
The severity of illness was rated using the CGI-S which is the key secondary endpoint. To perform this assessment, the rater or study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participant.
Baseline to Week 6
Mean Change From Baseline to Week 1, 2, 3, 4 and 5 Positive and Negative Syndrome Scale (PANSS) Total Score.
Ramy czasowe: Baseline to Week 1, 2, 3, 4, 5
The PANSS consists of 3 subscales (positive subscale, negative subscale and general psychology subscale) containing a total of 30 symptom constructs and was administered using the Structured Clinical Interview (SCI)-PANSS. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Baseline to Week 1, 2, 3, 4, 5
Mean Change From Baseline to Week 1, 2, 3, 4 and 5 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
Ramy czasowe: Baseline to Week 1, 2, 3, 4 and 5
The severity of illness was rated using the CGI-S. To perform this assessment, the rater or study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participant.
Baseline to Week 1, 2, 3, 4 and 5
Mean Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP)
Ramy czasowe: Baseline to Week 6
The PSP is a clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Baseline to Week 6
Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score
Ramy czasowe: Baseline to Week 6
For each symptom construct of the PANSS Positive Subscale, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The symptom constructs were as follows: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale Score for each participant was calculated as the sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score
Ramy czasowe: Baseline to Week 6
For each symptom construct of the PANSS Negative Subscale, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The symptom constructs were as follows: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale Score for each participant was calculated as the sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Clinical Global Impression- Improvement Scale (CGI-I) Score at Week 6
Ramy czasowe: Week 6
The participant's overall improvement was rated using the CGI-I. The rater or study physician rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared with the participant's condition at screening/baseline. Response choices were: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.
Week 6
Response Rate at Week 6
Ramy czasowe: Week 6
Response rate was defined as improvement in mean change of ≥30% from baseline in PANSS Total Score at Week 6 or CGI-I score of 1 (very much improved) or 2 (much improved) at Week 6.
Week 6
Mean Change From Baseline to Week 6 in PANSS Excited Component (PEC) Score
Ramy czasowe: Baseline to Week 6
The PEC consists of 5 PANSS items (excitement [P4], hostility [P7], tension [G4], uncooperativeness [G8], and poor impulse control [G14]). Each rated on a scale of 1 (absent) to 7 (extreme). The PEC for participants was calculated as the sum of the rating assigned to each of the 5 items, and ranged from 5 to 35 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Discontinuation Rate for Lack of Efficacy at Week 6
Ramy czasowe: Week 6
Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Score - Positive Symptoms Score
Ramy czasowe: Baseline to Week 6
The PANSS Marder Factor score - Positive Symptoms Score consists of 8 PANSS items (delusions [P1], hallucinatory behaviour [P3], grandiosity [P5], suspiciousness [P6], stereotyped thinking [N7], somatic concern [G1], unusual thought content [G9], lack of judgment and insight [G10]. Each was rated on a scale of 1 (absent) to 7 (extreme). The PANSS Marder Factor score - Positive Symptoms Score for participants was calculated as the sum of the rating assigned to each of the 8 items, and ranged from 8 to 42 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Change From Baseline to Week 6 in PANSS Marder Factor Score - Negative Symptoms Score
Ramy czasowe: Baseline to Week 6
The PANSS Marder Factor score - Negative Symptoms Score consists of 7 PANSS items (blunted effect [N1], emotional withdrawal [N2], poor rapport [N3], passive/apathetic social withdrawal [N4], lack of spontaneity and conversation flow [N6], motor retardation [G7], active social avoidance [G16]). The PANSS Marder Factor score - Negative Symptoms Score for participants was calculated as the sum of the rating assigned to each of the 7 items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Change From Baseline to Week 6 in PANSS Marder Disorganised Thought Score
Ramy czasowe: Baseline to Week 6
The PANSS Marder Factor score -Disorganized Thought Score consists of 7 PANSS items (conceptual disorganization [P2], difficulty in abstract thinking [N5], mannerisms and posturing [G5], disorientation [G10], poor attention [G11], disturbance of violation [G13], preoccupation [G15]). The PANSS Marder Factor score - Disorganized Thought Score for participants was calculated as the sum of the rating assigned to each of the 7 items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Change From Baseline to Week 6 in PANSS Marder Uncontrolled Hostility/Excitement Score
Ramy czasowe: Baseline to Week 6
The PANSS Marder Factor score - Uncontrolled Hostility/Excitement Score consists of 4 PANSS items (excitement [P4], hostility [P7], uncooperativeness [G8], poor impulse control [G14]). The PANSS Marder Factor score - Uncontrolled Hostility/Excitement Score for participants was calculated as the sum of the rating assigned to each of the 4 items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms.
Baseline to Week 6
Change From Baseline to Week 6 in PANSS Marder Anxiety Depression Score
Ramy czasowe: Baseline to Week 6
The PANSS Marder Factor score - Anxiety/Depression Score consists of 4 PANSS items (anxiety [G2], guilt feelings [G3], tension [G4], depression [G6]). The PANSS Marder Factor score - Anxiety/Depression Score for participants was calculated as the sum of the rating assigned to each of the 4 items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms.
Baseline to Week 6

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 lipca 2011

Zakończenie podstawowe (Rzeczywisty)

1 stycznia 2014

Ukończenie studiów (Rzeczywisty)

1 stycznia 2014

Daty rejestracji na studia

Pierwszy przesłany

11 lipca 2011

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 lipca 2011

Pierwszy wysłany (Oszacować)

18 lipca 2011

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

29 października 2015

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

29 września 2015

Ostatnia weryfikacja

1 września 2015

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 331-10-231

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Ostra schizofrenia

Badania kliniczne na Placebo

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Liberia

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj